Etrasimod arginine. Sphingosine-1-phosphate receptor 1 (S1P1 receptor) agonist, Treatment of ulcerative colitis

2020 ◽  
Vol 45 (3) ◽  
pp. 165
Author(s):  
J. Gras
Keyword(s):  
Ulcerative Colitis ◽  
Receptor Agonist ◽  
S1p1 Receptor ◽  
Sphingosine 1 Phosphate

Development of a selective S1P1 receptor agonist, Syl930, as a potential therapeutic agent for autoimmune encephalitis

2014 ◽  
Vol 90 (1) ◽  
pp. 50-61 ◽  
Author(s):  
Jing Jin ◽  
Jinping Hu ◽  
Wanqi Zhou ◽  
Xiaojian Wang ◽  
Qiong Xiao ◽  
...  
Keyword(s):  
Receptor Agonist ◽  
Therapeutic Agent ◽  
Autoimmune Encephalitis ◽  
S1p1 Receptor ◽  
Potential Therapeutic Agent

scholarly journals An Overview of Novel and Emerging Therapies for Inflammatory Bowel Disease

2020 ◽  
pp. 91-101
Author(s):  
Sumona Bhattacharya Sumona Bhattacharya ◽  
Raymond K. Cross Raymond K. Cross
Keyword(s):  
Ulcerative Colitis ◽  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Severe Disease ◽  
Gastrointestinal Symptoms ◽  
The Novel ◽  
Novel Therapies ◽  
Emerging Therapies ◽  
Sphingosine 1 Phosphate ◽  
Inflammatory Bowel

Inflammatory bowel disease, consisting of Crohn’s disease and ulcerative colitis, causes chronic gastrointestinal symptoms and can lead to morbidity and mortality if uncontrolled or untreated. However, for patients with moderate-to-severe disease, currently available therapies do not induce or maintain remission in >50% of patients. This underscores the need for additional therapies. In this review, the authors detail the novel therapies vedolizumab, tofacitinib, and ustekinumab and delve into therapies which may come onto the market within the next 10 years, including JAK-1 inhibitors (filgotinib and upadacitinib), IL-23 inhibitors (guselkumab, mirikizumab, and risankizumab), the anti-β4β7 and anti-βEβ7 integrin monoclonal antibody etrolizumab, the sphingosine-1-phosphate subtypes 1 and 5 modulator ozanimod, and mesenchymal stem cells. Further studies are required before these emerging therapies gain approval.

Indole-propionic acid derivatives as potent, S1P3-sparing and EAE efficacious sphingosine-1-phosphate 1 (S1P1) receptor agonists

2012 ◽  
Vol 22 (8) ◽  
pp. 2794-2797 ◽  
Author(s):  
Qinghua Meng ◽  
Baowei Zhao ◽  
Qiongfeng Xu ◽  
Xuesong Xu ◽  
Guanghui Deng ◽  
...  
Keyword(s):  
Propionic Acid ◽  
Receptor Agonists ◽  
S1p1 Receptor ◽  
Sphingosine 1 Phosphate

P356 Safety and PK results of a thorough QT/QTc (TQT) study of orally administered RPC1063, a novel, selective S1P1 receptor agonist

2014 ◽  
Vol 8 ◽  
pp. S213-S214 ◽  
Author(s):  
A. Olson ◽  
J. Hartung ◽  
G. Timony ◽  
R. Peach ◽  
M. Boehm ◽  
...  
Keyword(s):  
Receptor Agonist ◽  
S1p1 Receptor
Sign in / Sign up

Export Citation Format

Share Document